Skip to content
Advertisement

FILE - In this July 30, 2013, file photo, large banners hang in an atrium at the headquarters of Johnson & Johnson in New Brunswick, N.J. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions. (AP Photo/Mel Evans, File)

FILE - In this July 30, 2013, file photo, large banners hang in an atrium at the headquarters of Johnson & Johnson in New Brunswick, N.J. In a deal announced Thursday, Jan. 26, 2017, Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions. (AP Photo/Mel Evans, File)

Featured Photo Galleries